1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Zhejiang Tianyu Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    300702   CNE1000034X1

ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

(300702)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Zhejiang Tianyu Pharmaceutical : Raises $138 Million from Private Share Sale

01/18/2021 | 06:50pm EDT


© MT Newswires 2021
All news about ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
05/16Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2021
CI
04/22Zhejiang Tianyu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021
CI
04/21Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter..
CI
04/20MagicRNA announced that it has received $1.57 million in funding from Zhejiang Tianyu P..
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces 2020 Final Profit Distribution Plan ..
CI
2021ZHEJIANG TIANYU PHARMACEUTICAL : Pharma to List Over 1 Million Restricted Shares
MT
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Approves Cash Dividend for the 2020
CI
2021Zhejiang Tianyu Pharmaceutical Co., Ltd. Proposes Final Dividend for 2020
CI
More news
Financials
Sales 2022 3 301 M 493 M 493 M
Net income 2022 461 M 68,9 M 68,9 M
Net Debt 2022 - - -
P/E ratio 2022 27,4x
Yield 2022 0,63%
Capitalization 12 652 M 1 890 M 1 890 M
Capi. / Sales 2022 3,83x
Capi. / Sales 2023 3,06x
Nbr of Employees 4 991
Free-Float 37,6%
Chart ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Duration : Period :
Zhejiang Tianyu Pharmaceutical Co., Ltd. Technical Analysis Chart | 300702 | CNE1000034X1 | MarketScreener
Technical analysis trends ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 36,36 CNY
Average target price 41,47 CNY
Spread / Average Target 14,1%
EPS Revisions
Managers and Directors
Yong Jun Tu Chairman & General Manager
Yan Wang Chief Financial Officer & Board Secretary
Cheng Ma Chairman-Supervisory Board
Hai Zhi Ren Independent Director
Ji Yuan Shi Independent Director